Galaxy Balance

Ancient DNA can reveal how extinct species lived and evolved. New tools in genome engineering and reproductive biology may make it possible to recreate some of their traits, and to help endangered species adapt to changing environments.

Beth Shapiro, evolutionary molecular biologist and chief science officer at Colossal Biosciences, joins Galaxy Balance to discuss what de-extinction means in practice. We explore how researchers select traits from mammoth and elephant genomes, engineer many edits in elephant cells, and use different approaches for mammals and birds. Beth also explains how her team weighs animal welfare and genetic risk, why the direwolves were given light coats through a safer genetic route, and how local communities, Indigenous groups, and regulators can shape conservation plans.

The conversation covers the limits of ancient DNA, tools such as Genomorph, and the potential for technologies developed through de-extinction research to support biodiversity and conservation.

00:43 — Introduction to Dr. Beth Shapiro and the promise of de-extinction

01:55 — Beth’s path into ancient DNA and the appeal of reconstructing extinct worlds

03:31 — Why ancient DNA inspired Jurassic Park, not the other way around

04:20 — The first ancient-DNA breakthrough and the limits of recovering very old DNA

06:39 — Why mammoths became a central de-extinction target

08:50 — From early DNA sequencing to modern genomic tools

12:04 — How mammoth traits are selected from elephant and mammoth genomes

14:21 — Turning genetic differences into traits: hair, fat, ears, tails, and tusks

17:12 — Multiplex editing: making many genetic changes at once

19:29 — Genome integrity, off-target edits, and selecting healthy cell lines

24:11 — From edited cells to animals: cloning mammals and engineering birds

27:42 — The reproductive challenges of making mammoths and helping elephants

30:40 — Advancing bird genetics for dodo, moa, and conservation work

33:16 — Genetic rescue: engineering cane-toad-resistant quolls

35:31 — Regulation, local communities, and responsible phased releases

37:12 — Indigenous leadership and the moa restoration project

39:29 — Beth’s proudest achievement: expanding genetic tools for birds

44:06 — Can we restore traits without ancient DNA? The dire wolf example

48:09 — Why dire wolves will not be released into the wild

51:21 — Conservation over novelty: using genome editing to address biodiversity loss

53:49 — The biggest remaining technological hurdles

56:33 — “Playing God,” human responsibility, and shaping a biodiverse future

58:05 — Science-fiction recommendations and the enduring warning of Jurassic Park

Premature babies enter the world before many of their biological systems are ready, yet the technologies that keep them alive often separate them from their parents. Alon Metrikin-Gold, founder and CEO of NEOCare, is working to redesign neonatal care around connection.

His team developed SKINcubator, a wearable medical device intended to enable immediate and prolonged skin-to-skin care for premature and medically fragile infants. The device maintains warmth and humidity while securing the baby and supporting the lines and tubes required in intensive care.

In this episode, we explore why separation is not a neutral baseline, how physical contact affects stress regulation and development, and why parents should be treated as part of the clinical care team.

00:00 - Introduction to Skincubator Neocare and the problem of prolonged skin-to-skin care

01:11 - Alon’s background in women’s health and medical anthropology

03:03 - The key insight: separation is the artificial state

04:45 - WHO guidance versus actual NICU practice

06:14 - What parents and nurses revealed about failed skin-to-skin care

07:49 - Why extremely premature babies are so fragile

09:46 - The early engineering idea: heat and humidity from the parent’s body

10:43 - Six core design requirements for the first week of life

11:42 - What “transfer” means in practice and why it is so stressful

13:07 - Line safety, hypothermia, and why short sessions still fail

14:32 - How the device maintains heat, humidity, safety, and access

15:02 - Early clinical results and hours of skin-to-skin care achieved

16:19 - Target population and why the first days of life matter most

17:15 - Why NICU care often leaves parents unsure of their role

18:12 - How the broader system is built around separation

19:10 - Why skin-to-skin care is not just “nice,” but medically significant

21:06 - Human connection as something technology should support, not replace

22:04 - FDA breakthrough designation and what it means

23:32 - Why better documentation of skin-to-skin care matters

24:31 - How the device becomes a catalyst for protocol change

26:35 - The biology of stress reduction, cortisol, and stabilization

28:03 - Skin-to-skin care as preventative medicine and neurodevelopment support

30:28 - Maternal and infant benefits, including feeding and sensory regulation

31:25 - Designing as a producer, not an engineer, and listening to nurses

32:47 - Building for two user groups at once: parents and nurses

34:44 - How aesthetics, regulation, business model, and manufacturing all connect

36:29 - Funding the company with angels and seed capital

37:25 - Clinical expansion plans in Europe, Germany, Canada, Poland, Australia, and the US

38:10 - Safety, feasibility, and randomized trials focused on increased contact time

39:34 - Future outcome studies: baby, parent, nurse, hospital, and ROI measures

41:50 - The long-term roadmap: connected care from delivery to discharge

43:48 - Quantifying skin-to-skin barriers and the challenge of measurement

44:46 - Why parents occupy both patient and labor roles in the NICU

46:36 - Three strategic arcs: discharge, parent engagement, and low-resource settings

47:14 - Parenting, stress, and the emotional reality of the NICU

49:32 - Reimbursement, leave policies, and institutional barriers for families

55:13 - Advice for medical device founders: solve the problem, not the idea

56:42 - Why medical devices require technology, regulatory, and business model alignment

57:30 - Collecting data early to validate the next step

58:59 - Alon’s science fiction and urban fantasy recommendation

What happens when scientists rewrite the genetic code that nearly all life on Earth shares?

Dr. Akos Nyerges, a genome engineer and independent research group leader at Harvard Medical School, joins Galaxy Balance to explore the emerging world of synthetic genomes. His lab is engineering bacteria with altered genetic codes that can resist viral infection, restrict the exchange of genetic information, and incorporate chemical building blocks beyond biology’s standard 20 amino acids.

Akos explains how these genetic firewalls could make engineered organisms safer for drug delivery, biomanufacturing, and environmental applications. We examine why large-scale genome rewriting often produces sick cells, how multi-omics can reveal hidden errors such as accidental promoters and mistranslated proteins, and how his team restored recoded bacteria to near-normal fitness.

The conversation also explores AI-assisted genome design, cloud laboratories, engineered living medicines, horizontal gene transfer, the risks of mirror life, and the regulatory frameworks needed as synthetic biology moves toward increasingly ambitious forms of life.

Could we create organisms isolated from the rest of nature? Can evolution overcome even our strongest genetic firewalls? And how close is modern genome engineering to becoming science fiction made real?

00:00 Introduction
01:16 Akos’s Path to Synthetic Biology
03:59 Engineering the Genetic Code
05:45 Three Goals for Synthetic Biology
09:16 Controlling Horizontal Gene Transfer
11:11 Building a Genetic Firewall
13:39 Toxicity of Recoded tRNAs
14:26 Drug Delivery and Bioremediation
16:22 Solving the Fitness Problem
18:35 Measuring Real Biological Fitness
20:13 Testing Virus Resistance
23:37 Why the Genetic Code Is Universal
26:42 From Recoding to Applications
28:52 Debugging Genomes With Multiomics
31:15 Hidden Bugs in Genome Design
35:33 AI for Genome Design
37:51 Can LLMs Recode Genomes?
40:06 Building Local AI Compute
42:18 Cloud Labs and CROs
45:52 From Lab to Commercial Use
47:26 Translational Research and IP
48:44 Expanding Biology’s Chemical Alphabet
49:59 Ethics, Biosafety, and Regulation
53:23 The Risks of Mirror Life
57:37 When Science Fiction Becomes Real
58:33 Closing and Hiring Announcement

If the universe contains billions of potentially habitable worlds, where is everybody?

Dr. Terry Adair, author of Where Are the Little Green Men? The Adair Hypothesis, joins Galaxy Balance to examine the Fermi paradox through the lens of energy. His hypothesis proposes that an advanced technological civilization requires access to an abundant, dense, storable, transportable, and scalable energy supply.

The conversation traces Earth’s energetic evolution from hydrothermal chemistry and photosynthesis to fire, fossil fuels, nuclear fission, and fusion. Terry explains how photosynthesis enabled complex life while also creating the ancient reserves of coal, oil, and natural gas that eventually powered industrial civilization. He argues that this unlikely sequence may represent a series of filters preventing intelligent life elsewhere from producing detectable technology or reaching other stars.

We also explore the Drake equation, abiogenesis, the evolution of complex life, the technological limitations of ocean worlds, the challenges surrounding red dwarf stars, and the laws of thermodynamics that constrain every possible civilization. Terry outlines how fusion energy could eventually enable plasma drives, antimatter production, and spacecraft capable of reaching a meaningful fraction of the speed of light.

The episode closes with an optimistic vision of humanity’s long-term future. If we continue expanding our scientific knowledge and energy capabilities, humans may eventually become the interstellar visitors that other civilizations look toward the sky hoping to find.

00:00 - Why the Fermi paradox belongs at the center of this conversation

03:37 - How Adair’s background led him to an energy-based hypothesis

04:20 - What the Fermi paradox actually means

08:14 - Drake equation, exoplanets, and the Great Filter

10:23 - Why the Drake equation is a framework, not an exact answer

11:47 - Why abiogenesis and intelligence are not the same question

13:29 - Earth’s evolutionary milestones from microbes to technology

15:10 - Why photosynthesis is the breaking point in life’s history

18:28 - The difference between abundant energy and usable energy

21:49 - Endosymbiosis, mitochondria, and the energy jump in complex life

23:51 - Why CO2 is the raw material behind plant structure

26:19 - How biomass became coal, oil, and natural gas

29:25 - Where uranium and thorium come from

31:46 - Why nuclear fusion is central to future civilization

33:34 - Entropy, disorder, and why perpetual motion fails

38:03 - The limits of fossil fuels and the case for nuclear fission

40:02 - Weapons, waste, and why small modular reactors matter

43:20 - The Adair Hypothesis, defined

44:14 - Fire as humanity’s first technology

47:27 - The photosynthetic trap and why fossil fuels changed civilization

49:58 - How much energy humanity has burned in 200 years

51:21 - Could an aquatic species build technology without fire?

52:32 - From Democritus to quarks: what matter really is

56:22 - Why energy access on Earth is still an equity issue

58:51 - Antimatter, plasma drives, and propulsion limits

62:47 - Why fusion-powered travel is a 300 to 400 year project

64:21 - Humans as the future “little green men”

65:21 - Why Star Wars is Adair’s favorite science fiction reference

What if we could design a medicine for a single person?

Casey McPherson was a musician and songwriter when his daughter Rose was diagnosed with an ultra-rare neurogenetic disease. There was no approved treatment and no clear path forward. Rather than accepting that answer, Casey began learning genetics, building a network of scientists, and ultimately creating the infrastructure needed to develop a treatment for his daughter.

Today, Casey is the CEO and co-founder of Alpha Rose Therapeutics, where his team is working to make individualized genetic medicine scalable. Their approach combines antisense oligonucleotides, patient-derived stem cells, AI-guided therapeutic design, automation, and a new economic model for diseases that traditional drug development often leaves behind.

We discuss how Alpha Rose reduced a therapeutic amenability analysis that once took months to just minutes using AI, why Casey believes drug development should eventually be approved as a repeatable process rather than one drug at a time, and how point-of-care synthesis could allow personalized genetic medicines to be produced rapidly for individual patients.

We also explore autonomous laboratories, AI scientists, patient-derived iPSCs and brain organoids, the economics of rare disease, genetic enhancement, and a future of medicine that looks increasingly like the sick bay of Star Trek: understand the unique biology of the patient, design the intervention, synthesize it, and treat them.

Casey's story raises a much bigger question. Are rare diseases really rare, or are they the first glimpse of a future where every disease becomes individualized?

00:00 - Casey McPherson’s path from musician to biotech founder

01:38 - Childhood curiosity: music, programming, electronics, and biology

04:16 - Rose’s diagnosis and the end of the traditional care pathway

07:46 - Learning the problem was bigger than one child

09:59 - Why a foundation and ecosystem had to come first

11:27 - Why Rare Labs was built as a modality agnostic discovery lab

12:24 - Why antisense oligonucleotides made sense for Rose

13:22 - Designing and filtering thousands of ASO candidates

15:13 - Building patient-specific iPSCs and brain organoids

17:25 - Why animal models are mainly a safety tool

20:06 - Why Alpha Rose became a public benefit corporation

23:22 - Regulatory strategy and the path toward a small patient trial

27:35 - How Casey learned drug development by doing

30:30 - The AI amenability study workflow for new patients

33:24 - Turning a rough AI prototype into a validated internal tool

35:34 - Using the tool on every new drug and patient case

36:31 - Why speed matters when families are waiting on treatment

37:54 - Rare disease as a business model problem, not just a science problem

43:02 - The next decade of individualized medicine

44:27 - Process approval and point-of-care drug synthesis

46:34 - Beyond rare disease: enhancement and broader applications

48:24 - Why children’s health is so underfunded

51:20 - Why precision medicines can lower development risk

53:33 - Robotics and the fully automated lab of the future

55:46 - Renee, conversational AI, and the scientist-as-assistant future

56:54 - Science fiction influence and the Star Trek medicine model

59:50 - Advice for families and scientists facing genetic disease

1:02:21 - Closing thoughts on individualized disease

Could life be using quantum physics to sense the world, regulate cellular processes, and respond to magnetic fields?

Clarice Aiello is a quantum engineer, Chair of the Board and Chief Scientific Officer at the Quantum Biology Institute, and the founder of the former Quantum Biology Tech Lab at UCLA. Her research explores whether living systems harness quantum phenomena once considered too fragile to survive within warm, noisy cells.

In this episode of Galaxy Balance, Clarice explains quantum tunneling, superposition, entanglement, and decoherence through the lens of biology. We discuss how electrons inside proteins may function as nature-made quantum sensors, how weak magnetic fields can influence cellular behavior, and whether engineered magnetic fields could eventually support wound healing, regeneration, and other forms of electromagnetic medicine.

Clarice also describes the evidence that birds may use quantum sensing to navigate, why nature could teach us to build better quantum technologies, and how altered magnetic environments may affect organisms traveling to the Moon or Mars. We explore the scientific standards needed to move quantum biology into the mainstream, the limits of current evidence, and the possibility of creating a Star Trek-style tricorder that interacts with biology through precisely designed magnetic fields.

The conversation closes with quantum literacy, science fiction, interdisciplinary research, and Clarice’s advice for the next generation of scientists entering one of biology’s strangest emerging frontiers.

0:00 Clarice Aiello’s background and why quantum biology matters
7:12 The long-term vision for magnetic-field-based therapeutics
10:30 Why the field still lacks depth, breadth, and standards
15:30 What quantum physics is, in plain language
19:01 Superposition explained with dimmer-switch logic
26:19 Why decoherence limits quantum effects in warm, wet cells
29:27 What counts as evidence for quantum biology today
32:24 Skepticism about entanglement, microtubules, and consciousness claims
34:37 The double-slit experiment and why observation is often misunderstood
37:11 Mars, the Moon, and why magnetic fields may matter for colonization
41:37 How weak magnetic fields may work at the protein level
44:36 Spin-dependent chemical reactions and biological branching
53:14 Why Clarice thinks nature is effectively a quantum engineer
58:13 Science fiction, Recursion, and what it gets right and wrong about observation
59:05 Why quantum literacy should be part of basic education

00:00 - Introduction to Lily and GLife’s vision for data-driven dermatology

01:20 - Lily’s scientific background

02:43 - Breakthroughs from single-cell atlases

03:50 - The motivation behind founding GLife

04:50 - The importance of treating skin as a foundational organ

05:48 - Discovery of key molecular drivers of aging

06:22 - Challenges of fundraising

07:45 - The novel approach to rejuvenating hair loss through targeted messenger RNA treatments

08:53 - How treatments will be delivered via microneedles and micro patches

09:32 - The potential to alter hair color and explore cosmetic applications

10:06 - Balancing platform discovery engines with the development of first-in-class therapeutics

10:43 - The comprehensiveness of the skin atlas and addressing genetic diversity

11:39 - Technical challenges of capturing skin’s cellular heterogeneity and stem cell populations

12:50 - The importance of isoforms and deep sequencing in understanding gene functions

13:16 - Short-lived messenger RNA as a safe, reversible treatment modality

14:55 - Safety considerations and toxicity management

16:01 - Biodistribution studies and local micro-needle delivery safety

17:00 - Next steps towards clinical trials and regenerative therapies for hair loss

18:08 - The role of big data and omics in understanding skin disorders and aging

19:04 - The significance of isoforms in skin biology and gene function

20:13 - Endogenous vs. modified messenger design for safety and efficacy

21:32 - Potential for multi-gene delivery to enhance hair regrowth and color restoration

22:22 - Conception of patches that work with existing hair without shaving

23:38 - Targeting broad hair loss types and the concept of root causes

24:47 - Modeling hair loss with animal models and regulatory considerations

25:48 - Regulatory perspectives on non-animal models and validation strategies

26:34 - The interplay between genetic and environmental causes of skin aging

27:54 - The biological hub role of specific transcription factors in stress and aging

29:10 - The future of skin biomarkers for diagnosis and personalized health monitoring

30:18 - Leveraging AI’s data integration and precision medicine in dermatology

32:32 - The impact of protein isoforms and post-translational modifications in skin treatment

34:47 - Interest in peptides, small molecules, and biohacking trends for skin health

36:03 - Collaboration between wet labs, computational teams, and clinical partners

36:36 - The significance of internal naming conventions in research and development

37:28 - The high-throughput screening process for key transcription factors

38:13 - Strategies for overexpressing target genes in therapeutic design

39:00 - AI’s role in accelerating discovery and development pipelines in biotech

40:39 - Addressing data quality, heterogeneity, and integration challenges in big datasets

44:12 - Envisioning personalized skincare driven by genomics and AI

44:56 - The inspiring concept that ancient technologies now seem like magic

45:24 - Challenges in bringing novel dermatological treatments through trials and regulation

47:42 - The evolving role of AI in drug quality control and documentation

48:11 - Unique advantages of Lily’s targeted mRNA approach over other modalities

49:22 - Using skin as a model system for broader human biology insights

50:28 - Perspectives on epigenetic reprogramming and cellular re-differentiation

51:22 - Fundraising experiences and strategic positioning for biotech development

52:21 - The influence of science fiction, especially “Three Body Problem” and “Interstellar,” on Lily’s vision

54:24 - Advice to young scientists: read widely, think deeply, and dream big

What does it take to bring new chemistry to life?

In this episode of Galaxy Balance, Cory Smith speaks with Aditya Kunjapur, Associate Professor of Chemical and Biomolecular Engineering at the University of Delaware, about genetic code expansion, non-standard amino acids, engineered microbes, and the future of synthetic biology.

Aditya’s lab explores how biology can be programmed to biosynthesize chemical groups that are rare or absent in nature, install those new building blocks into proteins, and make microbial survival depend on synthetic chemistry. The conversation moves from his early path through energy and chemical engineering, to his time in George Church’s lab, to the founding of Nitro Biosciences and the use of expanded genetic codes for next generation vaccine platforms.

They discuss how non-standard amino acids can act as chemical flags for the immune system, how live microbes could produce antigens inside the body, and why genetic code expansion may open new approaches to vaccines, biocontainment, agriculture, environmental engineering, and planetary protection.

The episode also explores synthetic auxotrophy, engineered microbial dependence, plant controlled microbial survival, plastic degradation, agricultural probiotics, bioenergy, AI tools for non-standard amino acids, and the science fiction lessons behind containment, from Jurassic Park to modern AI.

This is a conversation about rewriting the language of life, not only to understand biology, but to give it new chemistry, new safeguards, and new possibilities.

Timestamps:

00:00 - Engineering microbes for space: Bacillus subtilis and biological containment
02:28 - Aditya’s pathway into synthetic biology and innovative chemistry
05:46 - Transitioning from industry internships to academia and entrepreneurship
10:16 - Founding Nitro Biosciences: balancing entrepreneurship with academic research
16:31 - Genetic code expansion and its potential to elicit immune responses
22:41 - The scarcity and potential of non-standard amino acids in life
27:26 - Detecting extraterrestrial life and the shared building blocks of biology
36:49 - Synthetic oxytrophy and microbial biocontainment strategies
44:01 - Reducing herbicide reliance with engineered microbes in agriculture
52:53 - Computational tools and AI for non-standard amino acid research
54:53 - Bioenergy and sustainability: bio-catalysis innovations
59:08 - How science fiction influences bioengineering and AI safety considerations

Erik Aznauryan, CEO and co-founder of HarborSite, joins Galaxy Balance to explore the next frontier of genome engineering: moving beyond small edits and toward precise, large-scale DNA insertion. Erik traces his path from Armenia and medical school to Europe, the Church Lab, and eventually founding HarborSite with a mission to make gene insertion safer, more durable, and more programmable.

The conversation dives into recombinases, safe harbor sites, payload size limits, delivery vehicles, in vivo validation, AI-driven protein engineering, and the therapeutic promise of inserting full genes or even entire genetic programs into the genome. Cory and Erik also discuss rare disease, cell therapy, skin and liver targeting, regulatory bottlenecks, animal models, funding shifts in biotech, and the long-term possibility of human enhancement in an age of AI.

At the edge of science fiction and translational medicine, this episode asks what becomes possible when genome engineering evolves from editing biology to writing biology at scale

00:00 — The North Star for genome engineering

00:36 — Introduction to Erik and HarborSite

01:39 — Erik’s path into science

02:36 — Early fascination with cloning and genome engineering

03:21 — Cory’s own early inspiration

04:03 — Why genome engineering matters

05:24 — Ethical questions around germline engineering

06:37 — Why early-stage intervention matters

07:51 — Technical progress and disease-specific editing

09:25 — Why HarborSite was founded

10:50 — Recombinases as the core technology

12:15 — Engineering recombinases for new DNA targets

13:12 — Novel genomic safe harbors

14:18 — How safe harbors are selected and validated

15:36 — How much target specificity can be changed?

16:36 — Why lifelong expression matters

17:29 — Testing durability in culture and in vivo

18:26 — The appeal of the albumin locus

19:15 — Endogenous production of biologics

20:59 — Startup challenges and fundraising

22:28 — Why LabCentral is valuable

23:07 — AI BioHub and large proprietary datasets

24:08 — AI’s role in model development

25:11 — Practical uses of AI in biotech startups

26:51 — How the team handles data analysis

27:56 — What the therapeutic product looks like

28:52 — First target tissues: liver and T cells

30:27 — Testing off-target integration

31:27 — Balancing specificity and efficiency

32:24 — Lessons from CAR-T and random integration

33:40 — Why recombinase systems may be safer

34:39 — Payload size and delivery constraints

35:35 — Delivery strategies under consideration

38:09 — Simpler donor DNA formats

39:38 — Platform company and therapeutic company

40:59 — The key milestone: in vivo validation

41:48 — HarborSite’s pre-seed raise

43:05 — How VC expectations have shifted

44:26 — Choosing the right in vivo model

46:22 — The continued importance of mouse studies

48:23 — Global regulatory differences

50:10 — Science funding in the U.S.

52:40 — Synthetic biology in space

54:34 — Enhancement and self-directed health

57:40 — Science fiction and inspiration

59:34 — Advice for young scientists

60:31 — Closing remarks

Max Rye and Evan Appleton of Intertwined Bio join Galaxy Balance to explore one of the boldest ideas in modern biology: borrowing nature’s most extreme traits and translating them into human health.

From horses that resist liver cirrhosis to naked mole rats, bowhead whales, radiation resistant organisms, hibernating animals, and the future of humans in space, this conversation asks what becomes possible when evolution itself becomes a design library. Max and Evan explain how Intertwined Bio is using synthetic biology, gene editing, AI, virtual macrophages, and agentic systems to identify traits from extraordinary animals and test whether those adaptations can be engineered into human cells.

We discuss liver fibrosis, DNA damage repair, innate immune engineering, longevity, space radiation, de extinction, Colossal Biosciences, the future of virtual cells, and the ethical line between therapy and enhancement.

This is a conversation about turning science fiction into biology.

00:00 - Introduction to Intertwined Bio and their innovative approach

01:01 - The origins and motivations of Max and Evan in biotech

04:56 - Scientific foundation: Borrowing traits from long-lived and resilient animals

07:16 - Why now? Recent technological advances enabling these innovations

10:46 - Role of AI in understanding complex biological systems and virtual cell modeling

14:17 - Delivery strategies for genetic modifications in humans

18:19 - Regulatory pathways and ethical boundaries in gene editing

22:25 - The potential of junk DNA variants and regulatory engineering

27:09 - The potential impact on sports animals and broader applications

31:12 - Industry landscape, collaboration, and competition

33:21 - Building a startup: team dynamics, trust, and early steps

35:58 - Insights on other biotech ventures like AstroMech and their directions

38:39 - Space applications: radiation resistance, hibernation, and life support systems

43:01 - Prioritizing targets using AI and high-throughput screening

48:31 - Broader prospects: aging, longevity, and the OZEMPIC effect

52:44 - Focus on innate immune system engineering and virtual cell development

57:15 - Strategies for macrophage gene editing and cell type targeting

1:01:36 - Bottlenecks in lab throughput and cell growth limitations

1:04:30 - The influence of science fiction on biotech innovation and ethical outlooks

1:06:14 - Closing thoughts: science fiction as inspiration and the rapid transition of ideas into reality

In this episode of Galaxy Balance, I sit down with Charles Fracchia to explore the emerging infrastructure layer of synthetic biology. We discuss the future of secure and scalable bioengineering, the role of community laboratories in accelerating innovation, and how biology is evolving into a programmable technology platform. Charles shares the story behind BioBright, the creation of Bio-ISAC, and the broader challenge of building resilient systems for a world where genetic engineering becomes increasingly accessible.

The conversation moves from cyberbiosecurity and open science to AI-driven biological design, scientific culture, and the growing overlap between software engineering and biotechnology. We also explore the long-term future of human enhancement, decentralized science, and how science fiction continues to shape the ambitions of the next generation of builders working at the frontier of biology.

Timestamps:

00:00 - Overcoming cynicism in AI's role in biosecurity

00:40 - Introduction to Charles Fracchia and his pioneering work

02:07 - Charles's background and journey into biotech innovation

04:01 - Balancing classical education with trial-by-fire experience

06:26 - AI as a search tool versus experimental center in biology

08:28 - Developing AI systems for biological experiment automation

11:35 - The founding and evolution of Black Mesa and its mission

14:26 - The importance of digital batch records and AI-assisted QA QC

16:06 - AI's role in drug development, safety, and traceability

18:44 - Ensuring trust and integrity in AI models for biotech applications

22:51 - Addressing data poisoning and ensuring model robustness

24:45 - Strategies for verifying biological data integrity through cryptography and blockchain

33:55 - Future threats like AI-driven bio weapons and safeguarding strategies

42:48 - The importance of operational innovation in accelerating bioeconomy growth

58:25 - Influence of science fiction on biosecurity and innovation

60:11 - Advice for emerging scientists in a rapidly changing landscape

1:02:53 - Closing remarks and future outlook from Charles Fracchia

What if the most powerful form of human optimization has nothing to do with biotech?

In this episode of Galaxy Balance, Cory sits down with Tyler Todt, who has built a platform around physical health, mental resilience, and intentional living. While the world races toward gene editing, AI, and synthetic biology, Tyler focuses on something more immediate: how daily habits, environment, and mindset shape the trajectory of your life.

They explore the tension between technological enhancement and human discipline, from fertility and genetic selection to Neuralink and simulated realities. Along the way, Tyler shares how small, consistent changes transformed his health, marriage, and purpose, and why most people fail by trying to do too much at once.

Timestamps:

00:00 - Small diet tweaks for improved energy and health

00:11 - The value of movement and daily habits in life optimization

00:44 - Introducing Tyler Todt’s background and mission

01:12 - Tyler’s journey from normal life to disciplined optimization

02:17 - Marriage, weight gain, and mental health struggles in the journey

03:08 - Creating intentional rules to improve life quality

04:08 - Mindset shifts for sustainable health improvements

04:45 - Challenges in maintaining motivation and overcoming setbacks

05:02 - Tips for starting small and building routines

06:01 - The neuroscience of habits and pattern creation

07:27 - The importance of grace and balance in biohacking

08:23 - Brain's autopilot and neural pathways in behavior change

09:16 - Ethical debates around reproductive biotech advances

09:43 - The use of stem cells in fertility and new treatments

10:32 - The future of gene editing and embryo selection

13:33 - Ethical considerations of genetic trait modification

15:35 - The potential dangers of designer traits and societal impacts

16:20 - Risks of focusing on narrow breeding goals

16:49 - Natural genetic variation and evolutionary trade-offs

17:09 - The double-edged sword of certain genetic traits like sickle cell

18:16 - Limitations of current genetic understanding and AI's potential

19:16 - Advances in DNA reading, writing, and CRISPR technology

20:03 - The ethical dilemmas of germline modifications and human enhancement

21:26 - The future of human evolution and the possibility of multiple iterations

22:16 - Space exploration, colonization, and interstellar travel

23:05 - The societal and ethical implications of AI-enhanced humans

24:33 - Neural interfaces, Neuralink, and virtual reality futures

25:35 - The allure and dangers of immersive digital worlds

26:13 - The role of genuine human experiences versus synthetic life

27:32 - The societal challenges of technological inequality

28:02 - The quest for extraterrestrial life and the Fermi paradox

39:15 - The potential for hidden advanced technologies and secret projects

40:44 - The vastness of space and the search for alien life

45:57 - Global cooperation and the importance of humanity's future

46:55 - UFOs, alien encounters, and government disclosures

49:40 - Living in a universe of uncertainties and existential risks

50:14 - Science fiction recommendations: The Matrix and beyond

50:53 - Advice for aspiring longevity explorers: control, curiosity, and consistency

52:25 - Mental health, nervous system management, and daily reflection

53:01 - Final thoughts and appreciation for innovative minds in health science

Genome editing has moved from experimental concept to FDA approved medicine in less than a generation. Few people have been closer to that transformation than TJ Cradick.

TJ was one of the earliest pioneers in programmable biology, helping shape the field from the era of zinc finger nucleases through the rise of CRISPR and next generation editing systems. As the second employee and Head of Genome Editing at CRISPR Therapeutics, he helped lay the scientific foundation for Casgevy, the first FDA approved CRISPR therapy. Later, at Excision BioTherapeutics, he worked on some of the first in vivo CRISPR therapies targeting latent HIV reservoirs.

In this episode, we dive deep into the evolution of genome engineering. We explore the transition from protein engineered nucleases to scalable CRISPR guide libraries, and the growing importance of delivery technologies capable of targeting tissues beyond the liver. TJ explains how off target analysis evolved from primitive assays into massively parallel sequencing pipelines and why the future of gene editing depends just as much on delivery and manufacturing as the editing enzymes themselves.

We also discuss the hidden challenges behind FDA approval, the realities of scaling genome editing therapies, the future of in vivo editing, and the ethical questions surrounding human germline engineering.

This conversation is a rare look inside the engineering, regulation, and philosophy of one of the most transformative technologies humanity has ever developed.

· 0:00 - Science Fiction to Science Fact

· 0:23 - Cutting Edge of Science

· 0:37 - Introduction to TJ Cradick

· 1:06 - CRISPR Therapeutics and Beyond

· 1:42 - Early Interest in Science

· 2:12 - Academic Journey

· 3:08 - Transition to Biotech

· 4:04 - Zinc Finger Nucleases

· 5:28 - Evolution of Screening Technologies

· 6:48 - CRISPR Libraries and High Throughput Screens

· 8:07 - New Technologies in Gene Editing

· 9:15 - Off-Target Effects and Assays

· 11:23 - Future Opportunities in Gene Editing

· 13:18 - Regulatory Challenges

· 16:24 - Cost Challenges in Genome Editing

· 18:22 - Manufacturing and Delivery Innovations

· 20:14 - Delivery Challenges and Innovations

· 22:30 - Capsid Design and Blood-Brain Barrier

· 24:01 - Viral vs. Non-Viral Delivery Systems

· 27:19 - IP Limitations and CRISPR Variants

· 30:31 - Target Selection for Therapeutics

· 34:03 - Precise Repair Technologies

· 37:03 - Off-Target Effects in Gene Editing

· 42:31 - Genetic Instability in Edited Cells

· 46:20 - Human Germline Engineering

· 49:19 - CRISPR for Viral Cure

· 51:27 - Regulatory Path Improvements

· 54:20 - Balancing Speed and Safety

· 57:03 - Advice for Future Scientists

What does it actually take to manufacture biology at scale?

In this episode of Galaxy Balance, Cory Smith sits down with Nabiha Saklayen, CEO and co-founder of Cellino, to explore the future of cell therapy manufacturing. Trained in physics and biophotonics, Nabiha is applying principles from semiconductor fabrication to one of the hardest problems in medicine: turning powerful cell therapies into scalable, reliable products.

The conversation dives into the core challenges of iPSC variability, autologous versus allogeneic strategies, and why manufacturing remains the primary bottleneck preventing these therapies from reaching patients. Nabiha explains Cellino’s approach, combining AI, imaging, and laser-based systems to create a closed, automated platform for cell production.

They also explore how AI is reshaping biology, how scientists are evolving into computational operators, and what the future lab looks like as automation and intelligence converge. From Artemis missions to the arrow of time in reprogramming, this episode connects physics, biology, and the long-term future of engineered life.

This is a deep look at the infrastructure layer of biofuturism and what must be true for living medicines to reach the world at scale.

00:00 - The importance of curiosity and bold thinking in science and technology

00:11 - Nabiha Saklayen’s background and childhood fascination with space

02:01 - Her journey through physics, biophysics, and motivations behind her work

03:24 - Early influences from diverse cultures and educational choices

06:17 - How personal loss shaped her scientific focus on biomedicine

08:40 - Insights on Artemis moon mission and space biology innovations

12:27 - Inspiring the next generation: fostering curiosity in children

14:20 - AI as a tool for biology and the significance of large language models

17:03 - The origins of Cellino: applying light-based manufacturing methods

20:22 - Cellino’s optical bioprocess and steps toward clinical-scale production

22:23 - Addressing variability in iPSC reprogramming and quality control

26:32 - Regulatory milestones and FDA collaborations in advanced therapies

30:27 - The role of automation and dashboards in scalable cell manufacturing

36:52 - Visualizing the process from donor cell to differentiated therapy

40:35 - Maintaining sterility and process control in cell banking

45:40 - How AI interfaces with robotics and the role of scientists in automated development

46:04 - The physics of cell removal using bubbles and laser technology

49:20 - How AI and machine learning optimize manufacturing processes and data management

54:54 - Advice for students passionate about science and innovation

57:19 - Future of human creativity and AI partnership in work and art

59:05 - Speculating on the creation or existence of AGI and its first questions

1:00:03 - The influence of science fiction on Nabiha’s worldview and recommended books

What if aging is not a collection of diseases, but a system-level failure we can intervene in?

In this episode of Galaxy Balance, Cory Smith sits down with Noah Davidsohn, co-founder and CSO of Rejuvenate Bio, to explore a new approach to longevity rooted in gene therapy and systems biology.

Noah’s work focuses on treating aging at its source by rebalancing key biological pathways across the body. Instead of targeting one disease at a time, his team is developing combination gene therapies designed to improve function across multiple organs simultaneously.

Rejuvenate Bio is currently raising on Wefunder. This is a rare opportunity to invest in a scaling biotech on the same terms as their VC partners. If our conversation resonated with you, this is your chance to join what Dr. Noah Davidsohn is building. Learn more and invest at http://wefunder.com/rejuvenatebio

00:00 - Replacing organs to reverse aging: science fiction or imminent reality

00:34 - Welcome to Galaxy Balance: exploring biology and AI frontiers

01:01 - Noah Davidson’s background and mission at Rejuvenate Bio

01:57 - Reprogramming biological systems for systemic healthspan extension

02:41 - The influence of sci-fi on Noah’s interest in space and longevity

03:38 - Space exploration's crossover with biological resilience

05:25 - The societal impact of science fiction on technological progress

07:55 - Addressing dystopian themes in modern sci-fi and their societal reflection

08:16 - The absence of longevity-focused sci-fi and Noah’s motivation

09:12 - Personal story: pet dog inspired Noah’s longevity work

10:33 - Origin of Rejuvenate Bio and its mission to treat aging

11:57 - Combining gene therapies targeting multiple age-related diseases

13:44 - The potential and limitations of epigenetic partial reprogramming

14:14 - Upcoming clinical trials and safety considerations for gene therapy

16:01 - Cyclic gene therapy and risks of permanent expression

17:43 - Inducible gene expression systems: safety and practical considerations

21:19 - Systemic, liver-targeted gene therapies: permanent vs. transient

22:33 - Strategies for pet therapies and expanding to human applications

25:47 - Manufacturing innovations reducing costs for wide-scale treatment

27:12 - Prophylactic use of gene therapies in pets and humans

29:08 - Targeting multiple diseases with a single systemic therapy

30:40 - Breeds at risk for mitral valve disease and targeted therapy efforts

33:42 - Disease-modifying treatments for fibrosis and heart failure

36:48 - How AAV vector delivery works and safety measures in tissue targeting

42:47 - Regulatory pathways for animal therapies and translational relevance

44:22 - Challenges in funding and VC environment for longevity startups

45:45 - The strategy of using animal models as a bridge to human therapies

50:05 - Future scientific directions: partial reprogramming and cell replacement tech

52:37 - The concept of longevity escape velocity and current progress

53:44 - Personal longevity practices: exercise, diet, sleep, stress management

55:27 - The role of biometric feedback devices in health monitoring

56:54 - Emerging modalities and innovative approaches in anti-aging research

58:24 - The ship of Theseus analogy for cell and tissue replacement

59:37 - Philosophical questions about consciousness and identity in aging

1:00:43 - Recommended sci-fi books for longevity and biotech enthusiasts

1:01:39 - Career advice for aspiring scientists and interdisciplinary innovation

1:02:45 - Wrap-up and best wishes for ongoing longevity breakthroughs

Synthetic biology is entering a new phase where biology can be treated as an engineering discipline. In this episode of Galaxy Balance, Cory Smith speaks with Dr. Tae Seok Moon, professor at the J. Craig Venter Institute and a leader in synthetic biology, about the long arc from reading DNA to eventually designing biological systems from first principles.

Tae shares his unconventional path into science. As a student in Korea he originally wanted to be a poet before choosing chemistry and engineering. that early philosophical curiosity about existence ultimately drew him toward biology and the story of life emerging from molecules after the Big Bang.

The conversation explores the evolution of synthetic biology through a literary metaphor. DNA sequencing allowed scientists to read the letters of life. Genome synthesis made it possible to write those letters. Gene editing introduced a way to revise existing text. Moon argues that most of modern biotechnology still resembles editing or copying nature rather than true creative writing in biology. Only recently have tools such as AI-guided protein design begun to generate entirely new biological "words."

Moon also discusses the legacy of Craig Venter and the creation of the first cell controlled by a synthetic genome. That milestone demonstrated that digital DNA stored in a computer can be turned back into a functioning biological system, a reversal of sequencing that points toward a future where genomes become programmable substrates.

The episode then moves into Moon's work at the intersection of space exploration and biotechnology. His team demonstrated that bacteria can produce the antioxidant lycopene in simulated microgravity using resources that would be available on the Moon or Mars. The system converts plastic waste into a carbon source and processes nutrients derived from human waste to fuel microbial production, a concept aimed at enabling sustainable life support systems during long-duration space missions.

Beyond space exploration, Moon leads global collaborations focused on transforming waste streams into useful chemicals and materials. He argues that the constraints of space missions mirror the resource challenges facing Earth today, from plastic pollution to carbon emissions. Technologies developed for closed-loop life support in space may also help build circular bioeconomies of Earth.

The conversation also tackles the rapid rise of artificial intelligence in biology, the future of scientific publishing, and the challenge of maintaining human creativity in an era of AI-generated research and communication. Moon reflects on what may remain uniquely human: genuine motivation, emotion, and the drive that comes from purpose and connection.

The episode closes with a story about one of Moon's former students who overcame severe adversity and later helped lead the development of a COVID vaccine. For Moon, that journey captures the deeper motivation behind science. The next generation of researchers will face immense challenges, but their work will shape the technologies that improve life across the planet.

This episode explores the frontier where biology becomes designable, where microbes may help sustain human life beyond Earth, and where the language of DNA may one day evolve from editing nature to composing entirely new forms of life.

0:00 - Introduction
1:01 - Tae Seok Moon Background
2:34 - From Poet to Scientist
8:26 - DNA as Language & Creation
12:37 - Synthetic Cells & Venter
18:31 - Microbes in Space
25:47 - ISS & Space Experiments
29:22 - Closed Ecosystems Challenge
32:25 - Solving Global Problems
37:44 - Science Fiction Influence
40:36 - AI in Synthetic Biology
50:38 - Future of Scientific Publishing
1:01:10 - Advice for Young Scientists

What if biology could be engineered the way we engineer software?

In this episode of Galaxy Balance, I'm joined by Pranam Chatterjee, Assistant Professor at the University of Pennsylvania and leader of the Programmable Biology Group, working at the intersection of AI, synthetic biology, and next-generation therapeutics.

Pranam's work is shaping a future where generative models can design peptides and biologics from sequence data alone, enabling a new era of programmable medicine.

We explore how Pranam went from studying religion and philosophy to transferring into MIT and building cutting-edge computational tools for biology. We dive into his time in George Church's lab, where early computational strategies helped spark the origins of Gameto, and how that work evolved into today's iPSC-derived ovarian support cell technologies now entering clinical trials.

From there, we go deep into the frontier of AI-driven molecular design:

• Do we actually need protein structure to design effective therapeutics?

• How do we optimize binding, toxicity, permeability, and immunogenicity simultaneously?

• What does "virtual cell" really mean, and why does mapping cell states matter?

• How close are we to "vibe coding biology," where natural language becomes the interface to biological engineering?

We also discuss the future of automation, robotics, and agentic AI in biology, as well as the ethical risks of democratized generative models in biotech.

This conversation is a window into the net phase of human capability: not just ready biology, but designing it.

00:00 - Introduction to AI-driven therapeutic peptide design
01:05 - Background of Pranam Chatterjee's journey from religion to science
02:50 - The evolution of AI models in synthetic biology
05:17 - Key milestones: from modeling to clinical applications like Gameto
08:19 - The founding story of Gameto and major breakthroughs
12:20 - Expanding into disease targeting and regenerative medicine
17:50 - The shift to virtual cell and organism design
22:16 - Tools for peptide design: Peptune and PEPMLM
25:04 - Generative modeling with language models and functional constraints
28:32 - Imagining programmable organisms and mythical creatures
29:41 - Hardware importance and future of vibe-coded biology
31:54 - The role of automation and robotics in biotech labs
33:47 - Mentoring students for the AI-biotech revolution
36:50 - Targeting rare diseases and regulatory considerations
40:34 - Global competition, safety, and ethics in biotech innovation
44:44 - Designing molecules with AI: from complexity to deliverability
45:09 - Data needs: where to find diverse biological datasets
47:49 - The rise of AI agents in scientific research
50:12 - Ethical responsibilities in AI bioengineering
52:38 - Safeguards against harmful biotech applications
55:22 - Thoughts on artificial general intelligence and human purpose
58:40 - How science fiction inspires biotech innovation
1:00:13 - Book recommendations and closing thoughts

In this episode of Galaxy Balance, Cory Smith speaks with Dr. Jonathan Scheiman, co-founder and CEO of FitBiomics, about the science of elite performance, microbiome discovery, and the future of metabolic health.

Jonathan shares his journey from Division I basketball player to biomedicine PhD and postdoctoral researcher in the Church Lab, where unconventional ideas are encouraged and ambitious biology is the norm

His central question was simple but radical: instead of studying disease, what if we studied peak human performance?

That question led to a longitudinal study of Boston Marathon runners, where his team collected microbiome samples before and after intense endurance events. The data revealed a striking pattern. One microorganism, Veillonella, spiked in abundance immediately after the marathon

Further analysis showed that this microbe uniquely metabolizes lactate and converts it into short-chain fatty acids such as propionate

Lactate is often misunderstood as a fatigue molecule. In reality, it is a normal metabolic fuel. When produced in excess during intense exercise, it accumulates in the bloodstream. Scheiman’s work suggests that a portion of circulating lactate is shuttled to the gut, where Veillonella uses it as a carbon source, producing metabolites that may support mitochondrial function, muscle recovery, glucose utilization, and anti-inflammatory pathways

The episode explores:

• How elite athletes may represent a rare biological phenotype comparable in rarity to centenarians
• Why the microbiome can shift rapidly in response to exercise intensity
• The challenges of culturing and scaling strict anaerobic microbes for commercialization
• The regulatory pathway differences between therapeutic microbiome interventions and consumer health products
• How AI and machine learning enabled the discovery of novel microbial signals in complex datasets

The conversation expands into longevity, mitochondrial efficiency, digital health integration, and the idea of FitBiomics as a biological data company rather than simply a probiotic brand

Scheiman also reflects on science fiction, pop culture, and storytelling as forces that shape technological ambition, drawing connections between Marvel, AI, and biotechnology innovation

This episode sits at the intersection of microbiome science, metabolic optimization, artificial intelligence, and the long-term future of human performance.

If the biology of elite athletes can be decoded and translated, the implications extend far beyond sport.

00:00 - Introduction to microbiome insights for human performance
02:20 - Personal journey from sports to biotech innovation
05:28 - How elite athletes inspired microbiome research
09:04 - Approaching human performance limits and societal health impacts
13:48 - Early discoveries: microbiome sampling from Boston Marathon runners
27:19 - The breakthrough finding: Vianella's role in fatigue and endurance
30:19 - Scientific steps to isolate and validate Vianella
33:29 - Regulatory considerations for microbiome supplements versus therapeutics
36:04 - Prevalence of Vianella across different athletes and individuals
40:51 - Microbiome as a dynamic, modifiable biomarker for health and sport
45:37 - Metabolism, mitochondria, and longevity interconnected through microbiome dynamics
49:16 - Influences of science fiction on biotech imagination and vision
57:39 - Future applications: wearables, continuous monitoring, and AI in microbiome health
1:00:46 - Vision for FitBiomics’ role in health innovation and societal impact

Biology is becoming programmable.

In this episode of Galaxy Balance, Cory Smith speaks with Yuanhao Qu, President and Co-Founder of PhyloBio, about the emergence of AI driven biological discovery. Yuanhao represents a new generation of scientists who combine genome engineering with large language models to build systems that can reason about DNA and accelerate research across the life sciences.

The conversation explores Yuanhao’s journey from early cancer research to developing CRISPR-GPT and Biomni, tools designed to help scientists design experiments, analyze data, and navigate the growing complexity of biological research. The discussion then moves to the founding of PhyloBio and the idea of an integrated biology environment where AI agents collaborate with human researchers.

We examine the future of genome engineering, the challenges of delivering gene therapies, and how AI agents may soon assist in designing experiments, generating hypotheses, and exploring massive biological datasets. They also discuss the possibility of automated laboratories, the evolving role of scientists in an AI-augmented research ecosystem, and the ethical boundaries that must guide advances in synthetic biology.

The episode closes with a discussion of science fiction, biosecurity, and the long term vision of AI systems that help humanity understand life at every scale.

If biology becomes a language, the next frontier will belong to those who learn how to speak it.

Phylo is a research lab developing cutting-edge agentic intelligence to accelerate discovery for biomedical scientists. They are building Biomni Lab, an integrated biology environment that leverages the latest AI to transform how biologists work. Explore it at http://biomni.phylo.bio

Phylo is also actively hiring. Learn more at http://phylo.bio/careers

Timestamps:

00:00 - Embracing rapid change and AI tools in biology
02:24 - Yuanhao’s background and motivation to cure cancer
04:11 - Analyzing complex diseases with genomics and AI
07:25 - Switching focus to AI-guided discovery and CRISPR engineering
12:13 - Building and deploying CRISPR-GPT to democratize gene editing design
16:23 - How AI enhances the role of scientists rather than replacing them
20:52 - The story behind PhiloBio and its vision to accelerate biotech innovation
24:01 - Developing BioOmni: an AI environment for biological research
28:21 - The future of AI in autonomous labs and the challenge of human-in-the-loop systems
36:33 - Ensuring safety and predicting oncogenic risk in genome engineering
42:49 - Advances needed in delivery mechanisms for gene therapies
45:02 - Insights into human intelligence evolution and AI’s role in discovery
51:04 - The significance of memory, personalization, and continuous learning in AI agents
55:06 - Ethical dilemmas in human germline modification and societal impacts
58:30 - Speculations on life’s prevalence in the universe and the Dark Forest hypothesis
59:46 - Advice for aspiring scientists eager to innovate with AI

In this episode of Galaxy Balance, Cory Smith is joined by Marc Güell, a synthetic biologist working at the frontier of genome engineering, AI-driven biological design, and translational therapeutics. Marc's work spans programmable genome integration systems, synthetic evolution, and the development of biological tools that extend far beyond what natural evolution has produced.

From his early training in chemistry and engineering to his time in the Church Lab at Harvard and now leading a research group in Barcelona, Marc's career reflects a consistent focus on building new biological technologies. The conversation explores how generative AI is reshaping genome writing, why engineering principles matter in biology, and what it takes to translate deep-tech synthetic biology into real-world applications.

We also discuss the founding of Integra Therapeutics, engineering the skin microbiome as a therapeutic platform, and how imagination influences real life science.

00:00 - How AI enables exploration of unconstrained genotypical spaces in synthetic biology
02:18 - Dr. Guell’s childhood in the Pyrenees fueling his passion for building and discovery
03:14 - From organic chemistry to synthetic genome engineering at Heidelberg and Harvard
05:33 - Recent advances in genome editing: CRISPR, xenotransplantation, and deep tech biotech startups
09:48 - The coming revolution: speaking DNA with AI tools and designing complex genetic circuits
12:30 - Navigating the vast, unconstrained genetic landscape using synthesis-free, AI-guided methods
15:44 - Exploring the complexity of splicing, gene regulation, and the role of AI in modeling biological systems
20:31 - Improving protein design and gene writing with coupled CRISPR and transposases
22:58 - Using AI-generated transposases surpassing natural biodiversity and expanding genotypic networks
27:09 - Strategies for safe, targeted insertions in gene therapy and cell engineering safety sites
30:20 - The mission of Integrate Therapeutics: commercializing AI-driven transposon technologies for cell therapies
34:50 - Challenges facing biotech startups and the need for strategic, cautious growth
39:42 - Engineering skin microbiomes for health and aesthetic applications, from acne to inflammation sensing
44:38 - The incredible potential of microbiome modulation for systemic health and space travel applications
46:46 - Ethical and safety considerations for AI-designed proteins and synthetic biology innovations
49:48 - Cross-cultural perspectives in science: Europe, the US, and China’s unique approaches and collaboration opportunities
51:59 - Automation and AI in experimental biology: new paradigms for high-throughput, in-silico evolution
55:18 - The impact of AI assistants and knowledge agents in accelerating scientific discovery
59:20 - The influence of science fiction: predicting and inspiring future biotechnologies
1:01:23 - Contemplating the nature of life, complexity, and the role of AI in understanding biology’s mysteries
1:04:25 - The power of imagination and science fiction in shaping the next generation of biotech breakthroughs